LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management. INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company and SiteOne Therapeutics, Inc ...

On May 27, Eli Lilly announced it would dish out $1 billion in cash to acquire SiteOne Therapeutics, a privately held biotech. 1 Underrated Reason to Buy This Market-Beating Stock Skip to main content ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

The buyout of SiteOne Therapeutics cost Eli Lilly $1 billion in cash. Then on June 17, Lilly announced it would acquire Verve Therapeutics, ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...

The buyout of SiteOne Therapeutics cost Eli Lilly $1 billion in cash. Then on June 17, Lilly announced it would acquire Verve Therapeutics, ...